ADMA BIOLOGICS, INC. (NASDAQ:ADMA) Files An 8-K Submission of Matters to a Vote of Security Holders
Item 5.07
ADMA Biologics, Inc. (the “Company”) held a Special Meeting of Stockholders (the “Special Meeting”) on August 23, 2019. At the Special Meeting, the following matters were submitted to a vote of stockholders:
(d) Exhibits
| 3.1 | Second Amended and Restated Certificate of Incorporation of ADMA Biologics, Inc. |
ADMA BIOLOGICS, INC. Exhibit
EX-3.1 2 e618626_ex3-1.htm SECOND AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF ADMA BIOLOGICS,…
To view the full exhibit click here
About ADMA BIOLOGICS, INC. (NASDAQ:ADMA)
ADMA Biologics, Inc. is a late-stage biopharmaceutical company that develops, manufactures and intends to market specialty plasma-based biologics for the treatment and prevention of infectious diseases. The Company is engaged in the development and commercialization of human plasma and plasma-derived therapeutics. Its segments include Plasma Collection Centers, which includes its operations in Georgia; Research and Development, which includes its plasma development operations in New Jersey, and Corporate. Its targeted patient populations are immune-compromised individuals suffering from an underlying immune deficiency disorder or may be immune-suppressed for medical reasons. Its product candidates are intended to be used by physician specialists focused on caring for immune-compromised patients at risk of contracting infectious diseases. Its intravenous immunoglobulin product candidate, RI-002, is intended for the treatment of primary immune deficiency disease.